References
- Borthakur G, El Ahdab S, Ravandi F, Faderl S, Ferrajoli A, Newman B, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma, 2008;49:690 – 695
- Silverman L R, McKenzie D R, Peterson B L, Holland J F, Backstrom J T, Beach C L, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol 2006; 24: 3895–3903
- Kantarjian H, Issa J P, Rosenfeld C S, Bennett J M, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1780
- Li L H, Olin E J, Buskirk H H, Reineke L M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970; 30: 2760–2769
- Jones P A, Taylor S M, Wilson V L. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983; 84: 202–211
- Creusot F, Acs G, Christman J K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 1982; 257: 2041–2048
- Rudek M A, Zhao M, He P, Hartke C, Gilbert J, Gore S D, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005; 23: 3906–3911
- Cashen A F, Shah A K, Todt L, Fisher N, Dispersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia or myelodysplastic syndrome. Cancer Chemother Pharmacol, in press
- Notari R E, DeYoung J L. Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. J Pharm Sci 1975; 64: 1148–1157
- Fenaux P, Mufti G J, Santini V, Finelli C, Giagounidis A, Schoch R, et al. Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimens: results of the AZA-001 Phase III study. Blood (Suppl.) 2007; 110: 817